Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06360055
Other study ID # M2024130
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2024
Est. completion date December 31, 2024

Study information

Verified date April 2024
Source Peking University Third Hospital
Contact Dongyang Liu
Phone (86)010-82266658
Email liudongyang@vip.sina.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate the effects of oral D-mannose tablets for 2 consecutive weeks on the pharmacokinetics of dabigatrun etexilate, a P-glycoprotein probe substrate drug, in healthy adults


Description:

This study is a prospective, sinale-center, open-label clinical studly, with adult healthy subiects as the research subjects. Healthy adult subjects will receive a single oral dose of 110mg (low dose specification in the instructions) or lower of dabigatran etexilate on day 1 and day 16 of the trial period. Blood samples for dabigatran plasma concentration determination at 0 h(before dosing)2 h, 4 h, 6 h, 12 h and 24 h after dosing will be taken. Subjects will take 3g (1g*3 tablets) of D-mannose tablets every morning and evening from the 2nd day to the 15th day of the trial period, with a total of 6g/day (medium dose specification in the instructions). Blood samples for detection of glycotomic serum concentrations such as D-mannose will be taken 0h before oral administration of dabigatran etexilate on day 1 and 1.5h after oral administration of D-mannose each morning on days 2, 8, and 15 of the trial period.


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date December 31, 2024
Est. primary completion date November 30, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: 1. With full capacity for civil conduct, the age of healthy male subjects is =18 years old and =45 years old 2. Male weight =50 kg; body mass index (BMI) within the range of 19.0~27.0 (including upper and lower limits) 3. Creatinine clearance rate (CRCL: calculated by Cock croft-Gault equation, adult healthy subjects should have CRCL=90mL/min Exclusion Criteria: 1. History of fainting of needles and blood. 2. Diseases affecting intestinal P-glycoprotein: severe diarrhea (excretion more than 3 times a day with watery stool characteristics), Crohn's disease, ulcerative colitis, irritable bowel syndrome, diverticulitis, difficult Identify Clostridium infection (recurrent) or Helicobacter pylori infection. 3. Diabetes mellitus; Impaired fasting glucose (IFG); Impaired glucose tolerance (IGT); Oral hypoglycemic agents (including the use of hypoglycemic agents for weight loss purposes). 4. Diseases or conditions with significant risk of major bleeding, such as current or recent peptic ulcer, malignant neoplasms with high bleeding risk, recent brain or spinal cord injury, recent brain, spinal cord, or eye surgery, recent intracranial hemorrhage, known or suspected Esophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracranial vascular abnormalities. 5. Clinically significant active bleeding. 6. Taking anticoagulants such as unfractionated heparin (UFH), low molecular weight heparin (LMWH) and heparin derivatives (fondaparinux sodium), vitamin K antagonists, rivaroxaban or other direct thrombin inhibitors (recombinant hirudin, bivalirudin); thrombolytic drugs, or current use of antiplatelet aggregation drugs such as GP?b/?a receptor antagonists, ticlopidine, prasugrel, dextran, sulfinpyrazone, aspirin, etc. 7. Use of drugs that may affect the activity of intestinal p-glycoprotein within 1 week before the trial: (1) potent p-glycoprotein inhibitors: amiodarone, verapamil, diltiazem, quinidine, dronedarone, tacrolimus, cyclosporine, protease inhibitors(indinavir, nelfinavir, saquinavir, lopinavir), macrolide antibiotics (erythromycin, clarithromycin, telithromycin, chloramphenicol), azole antifungal drugs (ketoconazole, itraconazole, Posaconazole, voriconazole, fluconazole, miconazole), nefazodone, cobicistat, cimetidine, ciprofloxacin, cyclosporin, fluvoxamine, imatinib, St. John's Wort, ranolazine; (2) Potent P-glycoprotein inducers: rifampicin, carbamazepine, phenytoin, phenobarbital, antiandrogens(enzalutamide, apalutamide), phenobarbital, dexamethasone. 8. Those who have a history of smoking and drinking in the past and who do not agree with the prohibition of smoking and drinking during the trial period: smokers (the average daily cigarettes smoked more than 5 cigarettes within one month before the test); alcoholism: (the average daily drinking within one month before the test=100mL high-quality liquor/200mL wine / 600mL beer). 9. History of gastrointestinal surgery such as gallbladder or appendectomy, bariatric surgery, etc. within the past 5 years. 10. Positive virological test (human immunodeficiency virus antibody (HIV-Ab), syphilis serological test, hepatitis B virus surface antigen (HBsAg) or hepatitis C virus antibody (HCV-Ab)) within 6 months before screening. 11. Those who have participated in clinical trials of any dug or medial device within 6 months before screening (in the case of drug clinical trials those who participated in the previous clinical trial before screening have more than 5 half-lives). 12. Subjects who are considered by the investigator to have any factors that are not suitable for participating in this trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dabigatran Etexilate
Subjects will receive a single oral dose of 110mg (low dose specification in the instructions) or lower of dabigatran etexilate on an empty stomach on the morning of day 1 and day 16 of the trial period.
Dietary Supplement:
D-mannose
Subjects will take 3g (1g*3 tablets) of D-mannose tablets every morning and evening from the 2nd day to the 15th day of the trial period, with a total of 6g/day (medium dose specification in the instructions).

Locations

Country Name City State
China Peking University Third Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking University Third Hospital

Country where clinical trial is conducted

China, 

References & Publications (3)

Dong L, Xie J, Wang Y, Jiang H, Chen K, Li D, Wang J, Liu Y, He J, Zhou J, Zhang L, Lu X, Zou X, Wang XY, Wang Q, Chen Z, Zuo D. Mannose ameliorates experimental colitis by protecting intestinal barrier integrity. Nat Commun. 2022 Aug 16;13(1):4804. doi: 10.1038/s41467-022-32505-8. — View Citation

Elmeliegy M, Vourvahis M, Guo C, Wang DD. Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies. Clin Pharmacokinet. 2020 Jun;59(6):699-714. doi: 10.1007/s40262-020-00867-1. — View Citation

Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33. doi: 10.1016/j.clpt.2003.09.012. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma concentration of dabigatran Plasma concentration of dabigatran will be measured by liquid chromatography-tandem mass spectrometry 0 hours before and 2, 6, 10 and 24 hours after administration of dabigatran etexilate on the day 1 and day 16 of the trial period.
Primary Serum concentrations of glycoomics such as D-mannose Serum concentrations of glycoomics such as D-mannose will be measured by gas chromatography-tandem mass spectrometry 0 hours before administration of dabigatran etexilate of day 1 and 1.5 hours after D-mannose administration in the morning of day 2, day 8 and day 15.
See also
  Status Clinical Trial Phase
Completed NCT03601715 - Analysis of Human Tissue Temperature After Application of Therapeutic Modalities. N/A
Completed NCT02145273 - Healthy Moms-Healthy Kids: Reducing Maternal Depression for Better Outcomes in Head Start Children N/A
Recruiting NCT01985152 - A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy Volunteers Phase 1
Active, not recruiting NCT00970398 - Effect of an Infant Formula on Infant Growth, Health and Immune Functions N/A
Completed NCT00332137 - Effects of Tolterodine, a Non-Specific Muscarinic Antagonist, on Gastrointestinal Transit in Healthy Subjects Phase 2
Recruiting NCT06060379 - Giochiamo 626 - Gaming for Health and Safety in Workplaces N/A
Completed NCT04998266 - Evaluation of Physical Capacities Within the Company and Effect of a Personalized Versus Traditional Training Program on the Quality of Life of Sedentary Employees N/A
Completed NCT01214278 - Bioavailability of Different n-3 Fatty Acid Formulations Phase 4
Recruiting NCT06157346 - Characteristics of Intestinal Bacteria and Their Effects on Growth and Immune Function in Children at High Altitude
Completed NCT01057368 - The Effects of Well-being Interventions on Affect, Attention, Sleep, Social Stress and Pain Regulation N/A
Completed NCT01216605 - Oxytocin and Emotion Recognition Phase 4
Completed NCT02287441 - Feasibility Study to Increase Vegetable Consumption N/A
Completed NCT01762553 - TEA for Families and Children: A Randomized Intervention Trial N/A
Completed NCT01123772 - Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers Phase 1
Completed NCT03527654 - SER Hispano Longitudinal Study
Recruiting NCT02132741 - Optical Coherence Tomography And NEphropathy: The OCTANE Study
Completed NCT03414346 - Analysis of the Effects on Human Tissues After Application of Therapeutic Modalities. N/A
Completed NCT02116283 - Mobile Sensing of Smoking Behavior N/A
Completed NCT05104385 - Hacettepe University COVID-19 Vaccinated's Health Cohort- Students of Health Sciences
Completed NCT00962195 - The Effect of Purple Sweet Potato (PSP)-Juice on Liver Enzymes and Blood Pressure N/A